NATIONAL-TSING
12.5.2020 11:02:12 CEST | Business Wire | Press release
On May 9 National Tsing Hua University entered into an agreement to jointly establish the Taipei School of Economics and Political Science (TSE) together with the TSE Foundation, which was set up with a US$100 million donation from entrepreneur Lin Chen-hai, the founder of the Pau Jar Group. The mission of the TSE will be to provide world-class education in economics, international politics, and public affairs, with Asia as the center of gravity, and will soon begin recruiting top-notch faculty from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200512005343/en/
At the signing ceremony, TSE Foundation chairman Huang Huang-hsiung said that the TSE will be located on the NTHU campus, and that this type of cooperation between the public and private sectors is a new first in the history of higher education in Taiwan.
Also present at the ceremony was Minister of Education Pan Wen-chung, who said that the establishment of the TSE is undoubtedly a new milestone for higher education in Taiwan. NTHU president Hocheng Hong said that the plan for establishing the TSE has already been approved by the Ministry of Education, and that it will soon begin recruiting master’s and doctoral students for the 2021-22 school year, two thirds of whom will be international students, adding that all courses will be taught in English.
Chairman Huang said that the TSE aims to attract outstanding students and world-class faculty, for which purpose he is helping to set up an international advisory committee, which includes four former ministers of education to arrange academic exchanges with such well-known institutions as the London School of Economics(LSE) and the Harvard Kennedy School.
NTHU president Hocheng Hong said that public-private cooperation in education on such a scale is unprecedented, pointing out that Lin’s US$100 million donation is the largest ever made in the field of social science education in Taiwan.
Hocheng asserted that technology is a major factor in all of the most pressing challenges facing humanity, such as food security, environmental preservation, energy, war, and even epidemics, and that any viable solution must take account of technological, political, and economic factors, adding that this was one of the principle motivations for establishing the TSE at National Tsing Hua University.
Hocheng said that the TSE will be the eleventh college at NTHU, and that its multi-disciplinary master’s and doctoral programs will be modeled on those of the LSE. The TSE plans to admit at least ten master’s students for the 2021-22 school year, and in the following school year at least 40 master’s students and ten doctoral students, after which enrollment numbers will gradually increase year by year. During the initial phase, TSE classes will be held in the Innovation Incubation Building on the NTHU campus, until the program’s own building is completed both on campus and in Taipei.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005343/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
